Interviews

Part 2: Surya Singh, MD, on Whether Biosimilars Will Lower Drug Costs

September 3rd 2020

Surya Singh, MD, president and owner of Singh Healthcare Advisors LLC in Lexington, Massachusetts, discussed the future for the US adalimumab market and whether biosimilars can deliver on the promise of lower cost health care.

Part 1: Surya Singh, MD, on Biosimilar Rebates and Payer Decisions

September 2nd 2020

Video

Surya Singh, MD, president and owner of Singh Healthcare Advisors LLC in Lexington, Massachusetts, discussed how payers’ decisions regarding formulary lists affect patient out-of-pocket costs and access to biosimilars.

Part 2: Cheryl Larson on What Employers Can Do to Influence Health Plan Decisions

August 27th 2020

Video

Cheryl Larson, president and CEO of the Midwest Business Group on Health, based in Chicago, Illinois, discussed what employers can do to get biosimilars added to their formulary lists and ensure their pharmacy benefit managers (PBMs) aren’t taking advantage of them.

Part 1: Cheryl Larson on How Employers Are Taking on PBMs

August 25th 2020

Video

Cheryl Larson, president and CEO of Midwest Business Group on Health, based in Chicago, Illinois, discussed how some employers are taking on pharmacy benefit managers (PBMs) to get biosimilars added to their formularies and what it could mean for biosimilar savings going forward.

Part 2: Swaminathan P. Iyer, MD, Discusses Changing the Infrastructure of Drug Access

August 20th 2020

Video

Swaminathan P. Iyer, MD, a professor of medicine in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discussed oncology biologics that are too costly for patients whether the Doha Declaration, which would enable governments to license the manufacture of these products, is a viable option.

Part 1: Swaminathan P. Iyer, MD, Discusses Need for Biosimilars in India, US

August 18th 2020

Video

Swaminathan Iyer, MD, a professor of medicine in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center, discussed the importance of biosimilars in India and the United States and the main concerns originator companies have regarding biosimilar competition.

Part 2: Nancy Globus on Whether or Not Biosimilar Naming Causes Confusion

August 13th 2020

Video

Nancy J. Globus, PharmD, vice president of Regulatory Affairs at the Accreditation Council for Medical Affairs (ACMA), discusses the truth behind 4-letter suffixes and product confusion among physicians and pharmacists.

Part 1: Nancy Globus, PharmD, Talks About the Purpose of Biosimilar Naming

August 11th 2020

Video

Nancy J. Globus, PharmD, vice president of Regulatory Affairs at the Accreditation Council for Medical Affairs (ACMA), discusses the history and controversy behind 4-letter suffixes used for biosimilars.

Part 2: Axinn Patent Attorneys Discuss New Challenges for Insulins Under the BPCIA

July 23rd 2020

Video

Ted Mathias and Stacie Ropka, PhD, intellectual property law partners with Axinn, Veltrop and Harkrider LLP, discuss patent disputes and interchangeability designations with regard to insulin products under the Biologics Price Competition and Innovation Act (BPCIA). This is Part 2 of the interview. To watch Part 1, click here.

Webinar: How Biosimilar Rebates Shape Payer Policies, Provider Behavior

July 22nd 2020

Video

A panel of experts discusses the ways in which payers restrict prescribing choices for physicians and what that means for the future of biosimilar utilization.